INTRODUCTION {#SEC1}
============

Faithful synthesis of proteins from mRNA templates is performed by ribosomes. These are highly complex nanomachines composed, in eukaryotes, of four ribosomal RNAs (rRNAs) and 80 ribosomal proteins ([@B1],[@B2]), assisted by translation factors and transfer RNAs (tRNAs). For optimal cell growth, human cells are estimated to synthesize about 7500 ribosomal subunits per minute, thanks to a highly coordinated choreography of more than 250 trans-acting factors that transiently associate with maturing ribosomal particles from the early step of rDNA transcription by RNA polymerases I and III in the nucleus to the final maturation steps in the cytoplasm ([@B3],[@B4]). This plethora of trans-acting factors is required for the synthesis, maturation, export and assembly of the ribosomal subunits.

Dysfunction of several ribosomal proteins and ribosome assembly factors is associated with pathologies called ribosomopathies, often associated with cancers ([@B5],[@B6]). While some factors have scaffolding or remodeling roles, others are directly involved in pre-rRNA processing (endonucleolytic cleavage, 5′ or 3′ trimming) or post-transcriptional modification (methylation, acetylation, ...), two highly coordinated mechanisms ([@B7]). With recent technological developments such as next-generation sequencing, highly sensitive mass spectrometry and atomic-resolution cryo-electron microscopy (cryo-EM), our current knowledge on rRNA and ribosomal protein modification is rapidly increasing ([@B8]).

The complete set of rRNA modifications has been described very recently for the 80S human ribosome, revealing the existence of 228 modifications of 14 different types ([@B10]). Most of these modifications are pseudouridylations and 2'-OH methylations catalyzed, respectively, by H/ACA and C/D box snoRNP complexes ([@B12]), but other, generally highly conserved modifications (methylation and acetylation) occur on bases ([@B13]). The most highly conserved modifications cluster at, or in the vicinity of important functional sites on the ribosome, including the decoding center, the peptidyl transferase center, the mRNA- and tRNA-binding sites, the entry of the peptide exit tunnel and the subunit interface ([@B13]).

Nucleotide modification is emerging as an important source of ribosome heterogeneity ([@B7]), consistent with the idea that cells produce compositionally different ribosomes with specialized functions in translation ([@B14],[@B15]). Yet the roles played by such modifications remain largely unclear, and identification of the enzymes responsible for depositing them lags far behind the discovery of the modifications themselves. Recently, progress has been made thanks to concerted efforts and the use of various model organisms such as *Saccharomyces cerevisiae* and archaea. In particular and very recently, a complete view has been obtained of the enzymes responsible for forming known 18S and 25S rRNA base modifications in *S. cerevisiae* ([@B13],[@B16]). This is rapidly leading to the study of their human orthologs.

Despite recent advances, the enzymes responsible for a few base modifications on human rRNAs have continued to elude identification. This applies, for example, to the N6-methyl-adenine (m^6^A) modifications at positions 1832 on human 18S rRNA and position 4220 (formerly 4190) on human 28S rRNA, both specifically detected over 30 years ago by RNase T1 and RNase A digestion of rRNAs isolated from human cells and other vertebrates ([@B17],[@B18]). The 18S rRNA m^6^A~1832~ modification is located in the 3′ minor domain of 18S, at the very base of helix h44, only a few nucleotides away from the decoding center (Figure [1A](#F1){ref-type="fig"}). The 28S rRNA m^6^A~4220~ modification is located in helix H81 of 28S rRNA domain V (Figure [1B](#F1){ref-type="fig"}). The enzyme involved in depositing the 28S rRNA m^6^A~4220~ mark has been identified very recently as ZCCHC4 ([@B19]), and we have confirmed it in this work. The enzymatic activity responsible for 18S rRNA m^6^A modification has escaped identification so far.

![METTL5 and ZCCHC4 are, respectively, the 18S and 28S rRNA m^6^A methyltransferases. (**A**) Ribbon representation of the human 40S subunit ([@B11]). Ribosomal proteins and 18S rRNA are colored light green and orange, respectively. Helix 44 (h44) of 18S rRNA is highlighted in magenta. The locations of m^7^G~1636~ and m^6^A~1832~ rRNA modifications are shown with red and cyan spheres, respectively. A 9-nt mRNA was modeled into the mRNA channel by superimposing the cryo-EM structure of mammalian ribosomal elongation complex bound to eEF1a and tRNAs ([@B74]). The mRNA codons corresponding to the A-, P- and E-sites are colored brown, blue and pink, respectively. Inset: Close-up view of the decoding site with some modified nucleotides highlighted. The anticodon loop of the tRNAs bound to the A-, P- and E-sites (delineated by dashed lines) are shown in brown, blue and pink, respectively. The methyl group of the m^6^A~1832~ nucleotide is shown as a black sphere. The tRNAs were modeled by superimposing the cryo-EM structure of the mammalian ribosomal elongation complex bound to eEF1a and tRNAs ([@B74]). (**B**) Ribbon representation of the human 60S subunit ([@B11]). Ribosomal proteins and 28S rRNA are colored light blue and beige, respectively. The respective locations of the m^6^A~4220~ rRNA modification and peptidyl transferase center (PTC) are shown as green and magenta spheres. CP: Central protuberance. Helix H81 of 28S rRNA is highlighted in red. (**C**) Human METTL5 is necessary for the formation of m^6^A on 18S but not on 28S rRNA. HPLC chromatograms (A~254nm~) of 18S rRNA (top panel) and 28S rRNA (lower panel) purified from *mettl5 -/-* clones and digested to nucleosides. The digested rRNAs purified from HCT116 parental cells (black curve) were used as controls. (**D**) Human ZCCHC4 is necessary for the formation of m^6^A on 28S but not on 18S rRNA. HPLC chromatograms (*A*~254\ nm~) of 18S rRNA (top panel) and 28S rRNA (lower panel) purified from z*cchc4* -/- clones and digested to nucleosides. The digested rRNAs purified from HCT116 parental cells (black curve) were used as controls.](gkz619fig1){#F1}

In the present study, we have identified METTL5 as the enzyme responsible for the 18S rRNA m^6^A~1832~. We show that METTL5 works in close association with TRMT112 and is stabilized by it. We have established the atomic-resolution structure of the METTL5--TRMT112 complex, revealing that, in a manner similar to the action of DNA methyltransferases, it may act by extruding the substrate adenosine from a nucleic acid duplex.

MATERIALS AND METHODS {#SEC2}
=====================

Human cell culture {#SEC2-1}
------------------

Unless specified otherwise, the experiments were performed in HCT116 p53-positive colon carcinoma cells (ATCC, \#CCL-247). The cell line was diagnosed by ATCC, by short tandem repeat (STR) analysis, prior to use. Cells were cultured in McCoy's 5A Medium (Lonza™ BE12-168F) in a New Brunswick Galaxy 170R incubator at 37°C and under 5% CO~2~.

For recording growth curves, the cells were detached and counted in a hemocytometer 24, 48 and 72 h after staining with Trypan Blue (Sigma, \#T8154). All measurements were performed in triplicate.

Generation of human cell lines deleted of METTL5 or ZCCHC4 by CRISPR--Cas9 genome editing {#SEC2-2}
-----------------------------------------------------------------------------------------

To delete from the genome the exon of METTL5 or ZCCHC4 carrying the methyltransferase signature, CRISPR guide RNAs (crRNA) were designed using <http://crispr.mit.edu> ([@B20]) near the exon--intron junctions. crRNAs with the best off-target scores ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}), tracRNA (IDT, \#1072532) and S.p. Cas9 (IDT, \#1081058) were purchased from Integrated DNA Technologies (IDT). Cells were transfected with *in vitro* reconstituted crRNA:tracRNA:Cas9 complex (final concentration 3 μM) and electroporation enhancer (IDT, \#1075915, final concentration 4 μM) in a nucleofector device (both versions IIb and 4D were used). Cells were incubated for 24 h to allow them to recover and then detached, and cloned (2D dilution series on 96-well plates). Cells from wells containing a single colony were detached, split into replicate 96-well plates and further incubated. Genomic DNA (gDNA) was extracted from one plate once cells reached confluence. By diagnostic PCR ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}), each target sequence with a deletion was detected. The PCR products were sequenced to establish the exact junctions of each deletion ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

Effect of TRMT112 on METTL5 metabolic stability in human cells {#SEC2-3}
--------------------------------------------------------------

A human cell line expressing an inducible METTL5-Flag construct was generated. For this, the coding sequence of METTL5 (NM_014168.4) was cloned into a pcDNA5-based vector for expression of a C-terminally Flag-tagged protein. The plasmid was used to transfect HEK293 Flp-In T-Rex cells (Thermo Fisher Scientific) and stably transfected cells were selected according to the manufacturer's instructions. In the selected cell line, METTL5-Flag was shown to be induced strictly upon addition of tetracycline. A tetracycline concentration between 0.01 and 0.1 μg/ml was sufficient to induce METTL5-Flag expression. To test the effect of TRMT112 on METTL5 metabolic stability in human cells, cells of the above-described cell line were depleted of TRMT112 for 3 days using an siRNA (siRNA LD068, [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). METTL5-Flag expression from the tetracycline-inducible promoter was triggered by the addition of tetracycline (between 0.01 and 0.1 μg/ml was used) 24 h prior to cell harvesting.

Analysis of modified nucleosides by HPLC {#SEC2-4}
----------------------------------------

The 18S and 28S rRNAs were purified from HCT116 cells and the *mettl5 -/-* and *zcchc4 -/-* clones by 10--50% sucrose velocity centrifugation. Briefly, 6 × 10^7^ cells were grown, detached, washed in ice-cold PBS and resuspended in 500 μl Buffer A: 20 mM Tris-HCl, pH 7.4, 50 mM KCl, 1 mM DTT, 0.5% NP40, Complete™ Protease Inhibitor (Roche \#COEDTAF-RO). The cell suspension was centrifuged at 20 000 × *g* for 20 min at 4°C, and the supernatant was stored at −80°C. Extracts were thawed on ice and loaded on a 10--50% sucrose density gradient (buffer A without protease inhibitor and DTT) and centrifuged at 23 000 × *g* for 20 h in a Beckman L-90K centrifuge with a SW41Ti rotor. The gradient was fractionated with an Isco density gradient fraction collector. RNA was extracted from peak fractions with TRIreagent (Sigma \#T9424), and an aliquot of recovered RNA was loaded on a denaturing agarose gel to check for RNA integrity and purity. Pure RNA fractions were pooled and the concentration was determined with a NanoDrop instrument. About 30 μg of 18S rRNA or 60 μg 28S rRNA was denatured at 95°C and snap cooled on ice. The RNA was then digested to single nucleotides for 16 h at 37°C in 6 mM sodium acetate/20 mM ZnSO~4~, pH 5.4 with 2 U of Nuclease P1 (Sigma, \#N8630) (total volume 50 μl). Subsequently, 10 μl Tris buffer (0.5M, pH 8.3) and 10 μl alkaline phosphatase (Sigma, \#P4252) were added and further incubated at 37°C for 2 h. HPLC analysis was performed essentially as described previously ([@B21]). Briefly, 50 μl digested nucleotides were analyzed on an Agilent 1220 Infinity LC system with a Supelcosil LC-18S column (Sigma, \#58298). The elution buffers were buffer A (0.01 M ammonium phosphate, pH 5.3, 2.5% methanol) and buffer B (0.01 M ammonium phosphate, pH 5.1, 20% methanol) and the elution program was (*A*\[%\]/*B*\[%\]/time\[min\]): 100/0/0, 100/0/12, 90/10/20, 75/25/25, 40/60/33, 36/64/37, 0/100/45, 100/0/60. Between each step, a continuous gradient was used. The m^6^A calibration control was purchased from Berry & Associates (\#PR 3732).

Crystallization and structure determination {#SEC2-5}
-------------------------------------------

Two crystal forms of the human METTL5--TRMT112 complex were obtained in the same drops at 4°C by mixing 1 μl of protein complex (2.7 mg/ml in Buffer L~200~) pre-incubated with S-adenosyl-L-methionine (0.75 mM) and 1 μl of reservoir solution (25% PEG 4000 in 0.2 M ammonium sulfate, 100 mM Na citrate pH 5.6). Crystals were cryo-protected by transfer to their crystallization medium supplemented with 15% and then 30% ethylene glycol before being flash-frozen in liquid nitrogen.

Several datasets were collected at 100K on Proxima 1 and Proxima 2A at synchrotron SOLEIL (Saint-Aubin, France) and processed with the XDS and AIMLESS programs ([@B22],[@B23]). Crystal forms I and II diffracted, respectively, down to 1.6 Å (one copy of the complex in the asymmetric unit) and 2.5 Å (two copies of the complex in the asymmetric unit).

The structure of the METTL5--TRMT112 complex was solved by molecular replacement with the program PHASER ([@B24]), using the dataset collected from crystal form I. Models of the METTL5 and TRMT112 protein structures were generated by the PHYRE2 server ([@B25]) using PDB codes, 1WY7 (39% sequence identity) and 5CM2 (35% sequence identity), as templates, respectively. The METTL5 and TRMT112 models were superimposed, respectively, onto the Bud23 and the Trm112 protein in the structure of the *S. cerevisiae* Bud23--Trm112 complex ([@B26]) and residues present in long loops were deleted to generate the search model used for molecular replacement. The final model for crystal form I was obtained by iterative cycles of building with COOT ([@B27]) and refinement with BUSTER ([@B28]) (for final statistics, see [Supplementary Table S6](#sup1){ref-type="supplementary-material"}). This model encompasses residues 3 to 190 and 198 to 209 (plus 2 histidine residues of the C-terminal His~6~-tag) for METTL5, and residues 1 to 118 for TRMT112, one SAM molecule, 5 ethylene glycol molecules, 2 sulfate ions and 320 water molecules. On the basis of electron density map analyses, METTL5 residues Cys38 and Cys110 and TRMT112 residue Cys33 were modeled, respectively, as s-hydroxycysteine, s-cysteinesulfinic acid and s-hydroxycysteine.

The structure of crystal form II was determined by molecular replacement, using the high-resolution structure of the METTL5--TRMT112 complex. The final model was obtained with the COOT and BUSTER programs, as described above. The model obtained contains residues 2 to 209 (plus 2 histidine residues of the C-terminal His~6~-tag) for METTL5 protomer A, residues 3--129, 136--188 and 198--209 for METTL5 protomer C, residues 1--12 and 20--118 (chain B) and 1--12 and 21--123 (chain D) for TRMT112, two SAM molecules, fragments of 3 PEG molecules, 2 ethylene glycol molecules, 7 sulfate ions and 28 water molecules. On the basis of electron density map analyses, TRMT112 Cys33 was modeled as s,s-(2-hydroxyethyl)thiocysteine, resulting from covalent adduction of 2-mercaptoethanol to the cysteine thiol in both TRMT112 molecules present in the asymmetric unit.

The atomic coordinates and structure factors have been deposited in the Brookhaven Protein Data Bank under accession numbers 6H2U (Form I) and 6H2V (Form II).

Transcriptome-wide single-nucleotide mapping of m^6^A by miCLIP {#SEC2-6}
---------------------------------------------------------------

Total RNA from wild-type, *mettl5-*knockout and *zcchc4-*knockout HCT116 cells was extracted in Tri Reagent (AM9738, Thermo-Fisher Scientific). Any contaminating genomic DNA was degraded with DNase I, and poly(A) RNA was purified with an mRNA isolation kit (NEB \#S1550) according to the manufacturer's recommendations. Five micrograms of poly(A)-selected RNA was then used as input for single-nucleotide resolution m^6^A mapping according to the miCLIP protocol, as previously reported ([@B29]). Final libraries were amplified and subjected to 50-cycle paired-end sequencing on an Illumina HiSeq2500 at the Weill Cornell Medicine Epigenetic Core facility.

Additional materials and methods details are available in the Supplementary Data.

RESULTS {#SEC3}
=======

Identification of the methyltransferases responsible for deposition of m^6^A~1832~ and m^6^A~4220~ on human 18S and 28S rRNAs {#SEC3-1}
-----------------------------------------------------------------------------------------------------------------------------

Although the presence of one m^6^A modification on each ribosomal subunit in metazoans was described more than 30 years ago ([@B17],[@B18],[@B30]), the enzymes responsible for depositing these methylation marks have remained unknown until now. Indeed, although methyltransferases constitute one of the largest enzyme classes in nature, the cellular substrates and functions of over 200 candidates remain unknown.

To identify the methyltransferases responsible for depositing m^6^A at A~1832~ on 18S rRNA and A~4220~ on 28S rRNA, we searched the UniProt database ([@B31]) for human proteins harboring an N6-adenosine-specific DNA methyltransferase signature (\[LIVMAC\]-\[LIVFYWA\]-(DYP)-\[DN\]-P-P-\[FYW\]; Prosite entry number: PS00092; ([@B32])). The rationale for doing so was that this signature is found in enzymes that methylate planar amino groups such as glutamine side chains in proteins (i.e.*E. coli* PrmC, eukaryotic Mtq2/HEMK2 ([@B33])) and exocyclic amino groups on DNA and RNA (forming m^2^G, m^4^C and m^6^A modifications; ([@B37])). This search resulted in seven hits including: (i) the HEMK1 and HEMK2 proteins, which methylate, respectively, the mitochondrial Mrf1 and cytoplasmic eRF1 translation termination factors on the side chain of a glutamine of a universally conserved GGQ motif ([@B33],[@B34],[@B38]); (ii) TRMT11, the human ortholog of the m^2^G~10~ tRNA methyltransferase; (iii) MGAM2, a membrane protein annotated as a probable maltase--glucoamylase and (iv) METTL4, METTL5 and ZCCHC4.

According to the Human Protein Atlas project ([@B39]), METTL4 is a mitochondrial protein, whereas in U2-OS human cells, METTL5 and ZCCHC4 localize to the nucleoli and nucleus, respectively (see [www.proteinatlas.org](http://www.proteinatlas.org)), i.e. the cell compartments where the initial steps of ribosome biogenesis take place. Furthermore, human METTL5 has been shown to bind specifically to RNA but not DNA ([@B40]). On the basis of phylogenetic analyses, the *HVO_1475* gene encoding the *Haloferax volcanii* METTL5 ortholog is proposed to be responsible for m^6^A formation at position 1432 on archaeal 16S rRNA ([@B41],[@B42]), corresponding to A~1832~ in human 18S rRNA. Altogether, these facts led us to investigate whether METTL5 and ZCCHC4 might be the enzymes responsible for m^6^A deposition on human rRNAs.

To test this hypothesis, we obliterated part of the coding sequence of each of these proteins on both alleles of diploid human cells (HCT116) by CRISPR--Cas9 genome editing. Specifically, we removed exon 3 from METTL5 and exon 7 from ZCCHC4, as both exons encode the \[N/D\]PPF signature of the putative methyltransferase domain (see [Supplementary Figure S1A and B](#sup1){ref-type="supplementary-material"}). To avoid known problems associated with off-target effects, we choose to expose cells only transiently to *in vitro* assembled CRISPR-Cas9 ribonucleoprotein particles (RNPs) (see 'Materials and Methods' and 'Discussion' section). Three independent *mettl5 -/-* cell lines (\#1, \#2 and \#3) and two independent *zcchc4 -/-* cell lines (\#1 and \#2) were isolated and the deletion of both alleles was validated by PCR on genomic DNA followed by genome sequencing in the edited area ([Supplementary Figure S1A and B](#sup1){ref-type="supplementary-material"}; [Supplementary Tables S1--S3](#sup1){ref-type="supplementary-material"} for details).

To test for a role of METTL5 and ZCCH4 in ribosomal RNA modification, mature 18S and 28S rRNAs were purified by velocity centrifugation from the different *mettl5-* and *zcchc4-*deleted cell lines and from isogenic HCT116 control cells (see 'Materials and Methods' section). They were then digested to nucleosides and analyzed by quantitative HPLC (Figure [1C](#F1){ref-type="fig"} and [D](#F1){ref-type="fig"}). In control cells, the m^6^A nucleoside was readily detected in both purified 18S and 28S, eluting just after 48 min (Figure [1C](#F1){ref-type="fig"} and [D](#F1){ref-type="fig"}) as expected ([Supplementary Figure S1C](#sup1){ref-type="supplementary-material"}). In all three *mettl5 -/-* clones, interestingly, the 18S rRNA m^6^A peak was lost, while the 28S rRNA m^6^A peak remained unaffected (Figure [1C](#F1){ref-type="fig"}). Conversely, in both *zcchc4 -/-* clones, the 18S rRNA m^6^A peak was unchanged while the 28S rRNA m^6^A peak disappeared (Figure [1D](#F1){ref-type="fig"}).

We conclude that METTL5 and ZCCHC4 are the elusive human methyltransferases responsible, respectively, for the formation of m^6^A~1832~ on 18S rRNA and m^6^A~4220~ on 28S rRNA. This conclusion is further supported by the structural analysis of METTL5 (see below, Figures [2C](#F2){ref-type="fig"},D and [3A](#F3){ref-type="fig"},B) and by transcriptome-wide single-nucleotide-resolution mapping of the m^6^A modification in the *mettl5-* and *zcchc4*-knockout cell lines (see below, Figure [4C](#F4){ref-type="fig"}). Our identification of ZCCHC4 as the 28S rRNA m^6^A-modifying activity is fully consistent with a recent report ([@B19]).

![METTL5 and ZCCHC4 are not essential to growth or ribosome biogenesis, and METTL5 gains metabolic stability by associating with human TRMT112. (**A**) Cell growth is not markedly affected in the absence of METTL5 or ZCCHC4. An identical number of cells of the indicated cell lines was seeded, and cell growth monitored every 24 h for 3 days by cell counting in an hemocytometer after staining with a vital stain. The experiment was performed in triplicate (s.d. shown in gray). (**B**) Mature rRNA production is not affected in the absence of METTL5 or ZCCHC4. Total RNA extracted from the indicated cell lines was resolved on a denaturing agarose gel and stained with ethidium bromide to reveal the mature 18S and 28S rRNAs. The 28S/18S ratio was extracted from Bioanalyzer electropherograms. (**C**) Atomic-resolution structure of the human METTL5--TRMT112 complex. The TRMT112 zinc-binding domain (ZBD) and its helical central domain are colored in purple and pink, respectively. The SAM molecule bound to METTL5 is shown as gray sticks. The methyl group transferred from SAM to the RNA substrate upon catalysis is depicted as a black sphere. Secondary structure elements of TRMT112 are labeled in italics. (**D**) Detailed representations of the METTL5--TRMT112 interface. Residues involved in the interface are shown as sticks. Residues of TRMT112 are labeled in italics. Asterisks (\*) indicate residues adopting two alternative conformations according to the 2Fo-Fc electron density map. The top panel shows the hydrophobic core of the interface, while the two other panels show the electrostatic interactions. Hydrogen bonds and salt bridges are depicted by black dashed lines. Same color code as in panel (C). (**E**) The metabolic stability of METTL5 depends on its association with TRMT112. Western blot analysis of the steady-state accumulation of METTL5 in the presence and absence of TRMT112. Synthesis of Flag-tagged METTL5 was induced by adding tetracycline (see 'Materials and Methods' section). TRMT112 synthesis was knocked down with a specific siRNA. Duplicated blots were probed with anti-Flag (METTL5 detection) or anti-WBSCR22 antibodies. As a loading control, the blot was probed with an anti-actin antibody.](gkz619fig2){#F2}

![Comparison of the active sites of METTL5--TRMT112 and of an N6-adenosine DNA methyltransferase from *Thermus aquaticus*, and structure of the m^6^A-methylated area in pre-40S and mature 40S subunits. (**A**) Superimposition of the METTL5--TRMT112 complex onto the M. TaqI--DNA complex (PDB code: 1G38). The m^6^A protruding into the active site of the M. TaqI methyltransferase is shown as sticks, and the N6 atom, on which the methyl group is grafted, is shown as a blue sphere. The DNA backbone is shown in orange. (**B**) Zoom-in on the active sites of METTL5 (yellow) and M. TaqI (light brown) (**C**) Superimposition of mature 40S (rRNA in orange; ribosomal proteins in green and assembly factors in gray; 11) and late pre-40S subunits (rRNA in gray, for the sake of clarity, the proteins and RNA corresponding to the head are not shown; 67). The WBSCR22--TRMT112 complex (blue for WBSCR22 and purple for TRMT112) as observed in state A of late 40S precursors is shown in ribbon representation (PDB code: 6G4W). Helix h44 is highlighted in magenta (mature 40S) and black (immature 40S). The m^6^A~1832~ as seen in the mature 40S is shown as cyan sticks and the N6 methyl group is shown as a sphere. The location of m^7^G~1636~ as seen in the cryo-EM structure of the mature ribosome is depicted by a red sphere. (**D**) Zoom-in on the region centered on position A~1832~, used to compare RNA conformations within the mature small subunit and late subunit precursors. Same color code as in panel (C).](gkz619fig3){#F3}

![Transcriptome-wide mapping of m^6^A by miCLIP reveals that METTL5 and ZCCHC4 are exclusively ribosomal RNA writers. (**A**) Metagene analysis of all m^6^A sites identified on mRNAs. The called m^6^A sites in each replicate were collapsed and plotted with the MetaPlotR pipeline ([@B75]). This shows the typical distribution of m^6^A, with enrichment at the stop codon and a high degree of overlap between the different conditions. DRACH, m^6^A modification consensus motif (D = A, G or U; R = A or G; H = A, C or U). (**B**) No other sites in the transcriptome are methylated by METTL5 or ZCCHC4. Coverage in sliding windows across each transcript was calculated and normalized per transcript. Differential bins between wild-type and each knockout were tested for significance with edgeR and plotted as a volcano plot. No sites in the transcriptome passed the false discovery rate (FDR) threshold of 0.1, indicating that no mRNA adenosines are methylated by METTL5 or ZCCHC4. (**C**) The genome track for the 47S pre-rRNA locus confirms that METTL5 and ZCCHC4 are the writers for m^6^A on the 18S and 28S rRNAs, respectively. C-to-T transitions are the most frequent substitution at m^6^A sites caused by antibody cross-linking. As both the 18S and 28S m^6^A marks are in a AAC context (red in the sequence shown below; the m^6^A is indicated by a red dot), reads were filtered for those containing CT to reduce background at this locus. The peaks for the 18S m^6^A and the 28S m^6^A (highlighted) are lost, respectively, in the *mettl5-* and *zcchc4-*knockout cells. The miCLIP sequencing data is available on the Gene Expression Omnibus database (accession number GSE128699).](gkz619fig4){#F4}

METTL5 and ZCCHC4 are dispensable for cell growth and ribosome biogenesis {#SEC3-2}
-------------------------------------------------------------------------

Having identified the enzymes responsible for human 18S and 28S rRNA m^6^A-methylation events, we examined whether these modifications might be important for cell growth and ribosome biogenesis.

First, cell proliferation was monitored for 3 days by manual counting after cell staining with a vital stain. The experiment, performed in triplicate, revealed that the absence of METTL5 or ZCCHC4 had no significant impact on cell growth (Figure [2A](#F2){ref-type="fig"}). Next, total RNA extracted from parental HCT116 cells and from all the independently isolated *mettl5 -/-* and *zcchc4 -/-* cell lines was subjected to denaturing agarose gel electrophoresis and ethidium bromide staining to reveal the mature 18S and 28S rRNAs (Figure [2B](#F2){ref-type="fig"}). Mature rRNAs were found to be produced normally in the absence of either METTL5 or ZCCHC4. This was confirmed by establishing the 28S-to-18S ratio from Bioanalyzer electropherograms: in all cases, this ratio was 1.0 (Figure [2B](#F2){ref-type="fig"}), as expected because the 18S and 28S rRNAs are produced by processing from a single long polycistronic transcript (see [Supplementary Figure S2A](#sup1){ref-type="supplementary-material"}). A detailed pre-rRNA processing analysis performed by quantitative high-resolution northern blotting revealed all the major pre-rRNA species with specific probes and showed no major differences ([Supplementary Figure S2B](#sup1){ref-type="supplementary-material"} and [Supplementary Table S4](#sup1){ref-type="supplementary-material"}). In the knockout clones, we noted a marginal increase in the steady-state level of the primary transcript (47S), but this had no impact on overall processing or mature rRNA production ([Supplementary Figure S2B](#sup1){ref-type="supplementary-material"} and Figure [2B](#F2){ref-type="fig"}).

In conclusion, METTL5 decorates the 18S rRNA with one m^6^A and ZCCHC4 installs another m^6^A on 28S rRNA. Neither enzyme is essential for cell growth or mature rRNA production nor is either of the deposited modifications.

Human METTL5 forms a heterodimer with TRMT112 to gain metabolic stability through the formation of a parallel β-zipper between main chain atoms {#SEC3-3}
-----------------------------------------------------------------------------------------------------------------------------------------------

To obtain structural information on the two newly identified m^6^A methyltransferases, we attempted their heterologous expression in *Escherichia coli*. Despite much effort, we found no experimental conditions allowing their overexpression in soluble form ([Supplementary Figure S3C and S3E](#sup1){ref-type="supplementary-material"}). As a growing number of eukaryotic RNA methyltransferases have been found to act as multimeric holoenzymes (e.g. [@B26],[@B43]), we investigated whether METTL5 and ZCCHC4 might also form multi-protein complexes.

Interestingly, in our recent study aimed at characterizing the interaction network of the methyltransferase activator Trm112 in the archaeon *H. volcanii*, we found the METTL5 ortholog *Hvo*\_1475 (hereafter called *Hvo*Mettl5, 35% sequence identity to METTL5), among the numerous methyltransferases co-purifying with *Hvo*Trm112 ([@B48]). This led us to test whether *Hvo*Mettl5 might interact directly with *Hvo*Trm112, and, by extension, whether human METTL5 might interact with TRMT112.

To test for the above-mentioned interactions, we co-expressed in *E. coli*, on the one hand, C-terminally His~6~-tagged *Hvo*Mettl5 with untagged *Hvo*Trm112 ([Supplementary Figure S3A](#sup1){ref-type="supplementary-material"} and [Supplementary Table S5](#sup1){ref-type="supplementary-material"}) and, on the other hand, His~6~-tagged human METTL5 with untagged human TRMT112 ([Supplementary Figure S3C](#sup1){ref-type="supplementary-material"}). As observed with Mtq2 (yeast)/HEMK2 (human), Trm9/ALKBH8, Bud23/WBSCR22 and several archaeal methyltransferases ([@B34],[@B48]), co-expression of *Hvo*Mettl5 with *Hvo*Trm112 and of METTL5 with TRMT112 led to successful overexpression of the relevant methyltransferase as a soluble protein ([Supplementary Figure S3A and C](#sup1){ref-type="supplementary-material"}). This was a first indication of direct *Hvo*Mettl5--*Hvo*Trm112 and METTL5--TRMT112 interaction.

Next, we applied a stringent 3-step purification protocol, beginning with His-tag-targeting affinity purification, to extracts of *E. coli* cells co-expressing either His~6~-tagged *Hvo*Mettl5 with *Hvo*Trm112 or His~6~-tagged METTL5 with TRMT112 (for details, see 'Materials and Methods' section). At the end of this protocol, SDS-PAGE analysis of the main peak eluting from the size-exclusion chromatography (SEC) revealed two bands (illustrated for the human METTL5--TRMT112 complex in [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}): one corresponding to the catalytic subunit (either *Hvo*Mettl5 or METTL5) and one corresponding to either *Hvo*Trm112 or TRMT112. The identities of these proteins were confirmed by mass spectrometry. We conclude that *Hvo*Mettl5 interacts physically with *Hvo*Trm112 and that human METTL5 associates directly with TRMT112. Size-exclusion chromatography coupled to multi-angle laser light scattering (SEC-MALLS) analysis of the purified proteins revealed the formation of heterodimers in solution in the cases of both the human (measured molecular weight of 41.6 kDa versus a theoretical value of 38.7 kDa) and archaeal (measured molecular weight of 29.9 kDa versus a theoretical value of 30 kDa) complexes ([Supplementary Figure S3B and D](#sup1){ref-type="supplementary-material"}). When ZCCHC4 was co-expressed with TRMT112, we observe no stabilizing effect ([Supplementary Figure S3E](#sup1){ref-type="supplementary-material"}). This is consistent with a recent study showing that ZCCHC4 can be successfully overexpressed in *E. coli* in the absence of any other human protein (see ([@B19]) and 'Discussion' section).

To learn more about the human METTL5--TRMT112 m^6^A rRNA methyltransferase complex, we determined its crystal structure at 1.6 Å resolution (final model with *R* and *R*~free~ values of 18.6% and 21.5%, respectively; [Supplementary Table S6](#sup1){ref-type="supplementary-material"}). We also obtained another crystal form diffracting at lower resolution (2.5 Å). The lower resolution diffracting crystal was interesting, as it allowed us to model a METTL5 loop encompassing residues 191 to 197, which was not defined in the higher resolution structure. This METTL5 loop includes part of the putative active site and contains a strictly conserved signature (see below). Since the structures of the complexes observed in the two crystal forms are virtually identical (rmsd of 0.7--0.8 Å), merging them provided a complete model of the human METTL5--TRMT112 (Figure [2C](#F2){ref-type="fig"}).

Human TRMT112 comprises two domains: a zinc-binding domain (or ZBD) and a central domain (Figure [2C](#F2){ref-type="fig"} and [Supplementary Figure S5A](#sup1){ref-type="supplementary-material"}). The ZBD is thus named by reference to previously determined crystal structures of several eukaryotic Trm112 proteins, where it was shown to contain four cysteine residues coordinating a zinc atom ([@B26],[@B35],[@B49],[@B54]). The ZBD is formed by residues of both the N- and C-terminal extremities of the protein and consists of an α-helix (α1) packed against a four-stranded anti-parallel β-sheet. In human TRMT112, remarkably, the four cysteines are not conserved and accordingly, the domain does not bind zinc ([Supplementary Figures S5A and S7](#sup1){ref-type="supplementary-material"}). The central domain consists of three α-helices (helices α2 to α4). The crystal structure of human TRMT112 superimposes on the structures of fungal Trm112 with rmsd values of 1.9 to 2.1 Å (over 110 Cα atoms; 35% sequence identity; 26,49,54) and on archaeal *H. volcanii* Trm112 with an rmsd value of 1.6 Å (over 50 Cα atoms; 37% sequence identity; 48).

The METTL5 protein consists of a single domain adopting a class I SAM-dependent methyltransferase fold composed of a central seven-stranded β-sheet flanked by four α-helices on one side (αY, αZ, αA and αB) and two on the other (αD and αE; Figure [2C](#F2){ref-type="fig"} and [Supplementary Figure S5B](#sup1){ref-type="supplementary-material"}). During refinement, an unambiguous electron density corresponding to SAM (the methyl donor) was observed in its expected binding site at the C-terminal face of the METTL5 central β-sheet, interacting exclusively with residues of METTL5.

The human METTL5 and TRMT112 proteins interact with each other through a large surface (area: 1160 Å^2^) formed by 29 METTL5 and 28 TRMT112 residues (Figure [2D](#F2){ref-type="fig"}). The interface is characterized by the presence of a large central hydrophobic core composed of residues V54, L76, V78, F80, M104, V105, M116, and F120 of METTL5, and L4, L8, L9, V35, F41, M45, L89, I113, P114, M116 and L117 of TRMT112 (Figure [2D](#F2){ref-type="fig"}; [Supplementary Figure S5A and B](#sup1){ref-type="supplementary-material"}). The hydrophobic interface is surrounded by polar residues involved in formation of eight hydrogen bonds and two salt bridges ([Supplementary Table S7](#sup1){ref-type="supplementary-material"}). Among these polar interactions, two hydrogen bonds are formed between the main-chain atoms of residues located in METTL5 strand β3 (Q106) and TRMT112 strand β4 (P114 and M116). They hence contribute to the formation of a parallel β-zipper between these two adjacent strands which, together, form a continuous eleven-stranded β-sheet (Figure [2C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}; [Supplementary Figure S7](#sup1){ref-type="supplementary-material"}). The two salt bridges involve the interaction of R115 and D121 of METTL5 with E102 and R44 of TRMT112, respectively (Figure [2D](#F2){ref-type="fig"} and [Supplementary Table S7](#sup1){ref-type="supplementary-material"}). All these characteristics of the METTL5--TRMT112 interface (hydrophobic core and β-zipper formation) are reminiscent of the previously described interaction mode through which eukaryotic Trm112 proteins contact their methyltransferase partners (namely Mtq2, Bud23, and Trm9; 26,35,47,54), and indeed, the structures of these complexes superimpose nicely on the structure of the METTL5--TRMT112 complex (rmsd values ranging from 2 to 2.5 Å over 230--250 Cα atoms; [Supplementary Figure S7](#sup1){ref-type="supplementary-material"}).

On METTL5, a very large hydrophobic surface, unfavorable in the hydrophilic cell environment, is masked by TRMT112 upon complex formation (Figure [2C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}; [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). As shown previously for its other partners ([@B47]), this observation suggests that TRMT112 may be required for METTL5 metabolic stability. This was indeed demonstrated by western blot analysis in a cell line expressing a C-terminal Flag-tagged construct of METTL5 under the control of a tetracycline-inducible promoter (Figure [2E](#F2){ref-type="fig"}). Flag-tagged METTL5 was detected only after the addition of tetracycline to the medium, and its steady-state accumulation was largely dependent on the presence of TRMT112 (compare odd and even lanes, with and without anti-TRMT112 siRNA). This indicates that TRMT112 is needed to stabilize METTL5. As a control, the blot was probed for another partner of TRMT112, WBSCR22, whose stability has been shown previously to depend on TRMT112 (Figure [2E](#F2){ref-type="fig"}; [@B52]).

Comparison of METTL5--TRMT112 with DNA and RNA m^6^A methyltransferases: implications for ribosome biogenesis {#SEC3-4}
-------------------------------------------------------------------------------------------------------------

Analysis of amino acid sequence conservation among METTL5 orthologs at the surface of the structure of the human METTL5--TRMT112 complex highlighted a large conserved surface around the SAM methyl group, very likely corresponding to the enzyme active site ([Supplementary Figure S5C](#sup1){ref-type="supplementary-material"}). This region is composed of the strictly conserved ^126^NPPF^129^ signature, a hallmark of methyltransferases that modify planar amino groups, plus the Glu27 and Tyr29 side chains of the \[L/F\]EQY motif present just upstream from helix αZ ([Supplementary Figure S5B](#sup1){ref-type="supplementary-material"}). Finally, the loop encompassing Phe192 and His193, which is disordered in our high-resolution crystal structure but visible in one of the two copies of the asymmetric unit in the low-resolution structure, is in close proximity to the putative active site and hence further extends it. This conserved region is also enriched in positively charged residues, in line with the view that the METTL5--TRMT112 complex functions as an RNA methyltransferase ([Supplementary Figure S5D](#sup1){ref-type="supplementary-material"}).

The mapping of sequence conservation at the surface of TRMT112 orthologs from multi-cellular eukaryotes revealed three conserved areas ([Supplementary Figure S6](#sup1){ref-type="supplementary-material"}): (i) the area involved in interaction with the methyltransferase subunit, (ii) a region overlooking the proposed METTL5 catalytic pocket (interestingly, in the context of yeast Mtq2--Trm112 and Trm11--Trm112 complexes, residues in this area have been shown to contribute to substrate binding, [@B35],[@B55]) and, finally, (iii) a third area on the solvent-exposed face of TRMT112, opposite the catalytic site of METTL5, which may be involved in interaction with yet to be identified factors.

To our knowledge, the structure of METTL5--TRMT112 is the fourth structure of a human m^6^A RNA methyltransferase to be determined, after those of METTL3--METTL14, METTL16 and CAPAM (cap-specific adenosine methyltransferase, also known as PCIF1; [@B45],[@B46],[@B56]-[@B60]). The METTL3--METTL14 holoenzyme, where METTL3 is the catalytic subunit and METTL14 is important for RNA recognition, modifies eukaryotic mRNAs, thereby specifically affecting the metabolism of m^6^A-containing mRNAs, i.e. pre-mRNA splicing, nucleocytoplasmic export, translation and degradation ([@B61]). The human METTL16 enzyme methylates U6 spliceosomal RNA and interacts at least with several non-coding RNAs and pre-mRNAs ([@B64],[@B65]). Interestingly, investigators have recently solved the crystal structure of human METTL16 bound to an RNA hairpin and with an adenine ring protruding into the active site ([@B57]). Lastly, CAPAM specifically methylates the base of the first transcribed nucleotide of eukaryotic mRNAs, when it is an adenine, to form m^7^Gpppm^6^Am ([@B60]). We therefore compared the structures of these three proteins (sharing between 7 and 16% sequence identity with METTL5) with that of METTL5--TRMT112. All three enzymes have the same overall architecture, although the topology of METTL3 differs from that of METTL5, CAPAM and METTL16 (rmsd values around 2.7--3.2 Å; [Supplementary Figure S8A, C and E](#sup1){ref-type="supplementary-material"}). Remarkably, the \[N/D\]PP\[F/W\] signatures of these different enzymes superimpose perfectly. Yet the other active-site residues conserved within the METTL5 family differ significantly from the corresponding residues in METTL3, METTL16 and CAPAM ([Supplementary Figure S8B, D and F](#sup1){ref-type="supplementary-material"}). Furthermore, a comparison with the RNA-bound structure of METTL16 shows that, with the exception of the NPPF signature, the residues coordinating the adenine ring in the METTL16 active site are not conserved in METTL5, and the METTL5 loop encompassing residues 184 to 200 sterically clashes with the RNA backbone. Altogether, this indicates that these enzymes might use distinct mechanisms to recognize the adenine base to be methylated.

Interestingly, when we compared the structure of METTL5--TRMT112 with those of m^6^A DNA methyltransferases bound to short double-stranded DNA fragments, we found unexpected commonalities (Figure [3A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"}). Of particular interest is the structure of DNA-bound *Thermus aquaticus* M. TaqI (rmsd value of 2--2.1Å over 140 Ca atoms; [@B66]), where the target adenine ring of one DNA strand extrudes from the double helix and points toward the active site, where it is coordinated by the ^105^NPPY^108^ signature and the Val21 and Phe196 side chains (Figure [3A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"}). These correspond respectively to ^126^NPPF^129^, Tyr29 and Tyr184 of human METTL5, which we suggest might coordinate the target adenine in its active site as does M. TaqI, optimally positioning the adenine for transfer of the SAM methyl group onto its N6 atom (Figure [3B](#F3){ref-type="fig"}).

In the structure of the mature human 40S subunit ([@B11]), the m^6^A~1832~ nucleotide is located in the decoding center area, in a short region connecting 18S rRNA helices h44 and h45. It is base-paired with C1703, making it poorly accessible (Figure [1A](#F1){ref-type="fig"}). In the recent structures of late human 40S subunit maturation intermediates bound either to the WBSCR22--TRMT112 complex or to the NOB1, PNO1 and RIOK2 assembly factors ([@B67] and see below), the decoding center is not completely matured, and A~1832~ is not defined in the cryo-EM electron density map due to increased flexibility (Figure [3C](#F3){ref-type="fig"} and [D](#F3){ref-type="fig"}). In 40S precursors, the base-pairing involving nucleotides surrounding A~1832~ is similar to that observed in mature 40S, but the top of helix h44 is bent outward by 20° relatively to its position in mature subunits (Figure [3C](#F3){ref-type="fig"}). As a consequence, the distance between nucleotides C~1828~ and G~1836~ increases from 27 Å in the mature form to 32 Å in the immature form (Figure [3D](#F3){ref-type="fig"}). This conformation stretches this rRNA region and very likely results in melting of the hairpin formed in mature rRNA by nucleotides m^6^A~1832~ to G~1836~ leading, in the immature form, to the exposure of the A~1832~ base to the solvent. During the late processing steps, this nucleotide would then be located at the center of a region connecting helices h44 and h45, poised to be recognized by the METTL5--TRMT112 complex in a manner highly reminiscent of the recognition of double-stranded DNA by the M. TaqI enzyme ([@B66]) (Figure [3A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"}).

Despite extensive efforts, we were unable to recapitulate METTL5--TRMT112 enzymatic activity *in vitro* with short single- or double-stranded RNAs corresponding to the sequences surrounding m^6^A~1832~ in the mature ribosome. This precludes further structural studies with RNA fragments.

METTL5 and ZCCHC4 are exclusively m^6^A ribosomal RNA writers {#SEC3-5}
-------------------------------------------------------------

Finally, as cases of cross-talk are emerging where a particular RNA modification machinery appears to act on multiple classes of cellular and even viral RNAs ([@B21],[@B64],[@B65],[@B68]), we wondered if METTL5--TRMT112 or ZCCHC4 might act on RNA substrates other than ribosomal RNAs.

To answer this question, we used the miCLIP technique to perform systematic single-nucleotide resolution mapping of m^6^A on the transcriptome of human cells lacking either METTL5 or ZCCHC4 (see 'Materials and Methods' section). Two independent knockout cell lines for each methyltransferases were tested in parallel. While 12 346 m^6^A sites were re-mapped on mRNAs of isogenic control cells, no position within either mRNAs or long non-coding RNAs was found to vary significantly in the absence of METTL5 or ZCCHC4 (Figure [4A](#F4){ref-type="fig"} and [B](#F4){ref-type="fig"}). The miCLIP analysis further confirmed that METTL5--TRMT112 is responsible for installing m^6^A~1832~ on 18S rRNA and ZCCHC4 for depositing m^6^A~4220~ on 28S rRNA (Figure [4C](#F4){ref-type="fig"}). In conclusion, METTL5 and ZCCHC4 are highly specific, respectively, to the 18S and the 28S m^6^A modification.

DISCUSSION {#SEC4}
==========

Eukaryotic ribosomes are heavily modified. During ribosomal subunit biogenesis, many rRNA nucleotides, often in functionally important regions of the ribosome, are specifically selected to be modified either by snoRNP-based nanomachines or by more conventional protein-only enzymes ([@B13]). Yet the diversity of ribosomal RNA modifications appears rather limited, as yeast ribosomes have been found to contain only 12 types of RNA modification out of a so-far-uncovered natural repertoire of 163 ([@B13]). Apart from 2'-*O*-methylated sugars and pseudouridines, which constitute the bulk of rRNA modifications, yeast ribosomes carry only 12 base modifications, six on the small and six on the large subunit. Not until recently has the entire set of modification enzymes responsible for installing these rRNA modifications been identified in yeast ([@B16]). Because these rRNA base modifications are highly conserved throughout the eukaryotic kingdom, most of them being present also on human ribosomes, the human orthologs of the identified yeast enzymes are being characterized. Yet human ribosomes carry at least one additional RNA modification type: m^6^A, one on each subunit (Figure [1A](#F1){ref-type="fig"} and [B](#F1){ref-type="fig"}). These modifications have no equivalent in yeasts, and the activities responsible for depositing them have remained unknown for 33 years ([@B17],[@B18]).

In the present work we have identified METTL5 and ZCCHC4 as the m^6^A methyltransferases responsible, respectively, for 18S and 28S rRNA modification. We have identified these novel m^6^A methyltransferases by screening bioinformatically the human proteome for candidates harboring an N6-adenosine-specific DNA methyltransferase motif. Our quantitative HPLC data (Figure [1C](#F1){ref-type="fig"} and [D](#F1){ref-type="fig"}) and single-nucleotide-resolution miCLIP analysis (Figure [4C](#F4){ref-type="fig"}) demonstrate that the activities identified are indeed responsible for 18S and 28S rRNA m^6^A methylation. To our knowledge, this is the first report of a function for METTL5. We also confirm the role of ZCCHC4 ([@B19]). Our miCLIP analysis further reveals, for the first time, that both enzymes act only on ribosomal RNAs (Figure [4A](#F4){ref-type="fig"} and [B](#F4){ref-type="fig"}). For METTL5, we provide evidence that it must form a heterodimer with TRMT112 to gain metabolic stability in cells (Figure [2E](#F2){ref-type="fig"}). We have also determined the atomic-resolution structure of the METTL5--TRMT112 complex, highlighting the molecular nature of the interface between the two subunits: a parallel β-zipper between main-chains atoms (Figure [2C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}). The use of main-chain rather than side-chain atoms to form the interface enables TRMT112 to form such complexes with other methyltransferases sharing the same fold but displaying only limited sequence homology (see below and discussions in [@B26],[@B47],[@B54]).

Upon comparing the structure of METTL5--TRMT112 with those of three recently described human m^6^A methyltransferases, namely METTL3--METTL14 ([@B45],[@B46],[@B56]), METTL16 ([@B57]) and CAPAM ([@B60]), we observed no major similarities ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}). This suggests that METTL5--TRMT112 likely operates in its own specific way. Interestingly, however, a comparison of METTL5--TRMT112 with an N6-adenosine DNA methyltransferase of *Thermus aquaticus* (M. TaqI) revealed that METTL5--TRMT112 might extrude the substrate adenosine from a nucleic acid duplex (Figure [3A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"}). Consistently with this initial mechanistic insight, a comparison of the structure of the modified area in precursor and mature forms of 18S rRNA indicates that in maturing subunits, the RNA segment containing A~1832~ is 'stretched' by ∼5 Å. This may increase the accessibility of the target adenosine by 'flipping it out', thus exposing it to the catalytic site of the enzyme (Figure [3C](#F3){ref-type="fig"} and [D](#F3){ref-type="fig"}).

Among the various m^6^A RNA methyltransferases identified so far, two appear to work as holoenzymes, METTL3--METTL14 and METTL5--TRMT112. The METTL3 mRNA m^6^A methyltransferase indeed strictly requires METTL14 as a coactivator. METTL14 has divergently evolved from a class I SAM-dependent methyltransferase fold, but it has lost both its ability to interact with SAM and its active site ([@B45],[@B46],[@B56]). It is assumed, however, to be essential for the binding and proper positioning of the mRNA substrate in the METTL3 active site. Thus, METTL5 is the second reported example of an m^6^A methyltransferase strictly requiring a coactivator, in this case TRMT112.

The folds adopted by METTL14 and TRMT112 are radically different, yet TRMT112 shares functional communalities with METTL14. On the basis of the striking similarities between the structures of the METTL5--TRMT112 complex and of previously characterized heterodimeric complexes formed between Trm112 and other methyltransferases, TRMT112 is expected not only to be important in stabilizing METTL5 but also to activate METTL5 by stimulating its SAM-binding capacity ([@B35],[@B55]). However, a stimulatory role of TRMT112 on METTL5 catalysis remains to be formally demonstrated. In addition, if our proposed docking of the METTL5--TRMT112 complex onto pre-40S state 'E' is correct (see below, Figure [5](#F5){ref-type="fig"}), then TRMT112 appears to be in contact with the 40S ribosomal subunit, thereby directly contributing to the substrate-binding capacity of the catalytic subunit METTL5.

![Tentative positioning of the METTL5--TRMT112 complex within the maturing ribosomal small subunit. (**A**) Five sequential stages (states 'A' to 'E') in the late maturation of human 40S subunit established by cryo-EM ([@B67]). Orange dot, site of m^6^A modification at the ribosomal decoding site. Only state 'E' exhibits in the A~1832~ area an unassigned density that could be ascribed to METTL5--TRMT112 (see panel B). In states 'A', 'C' and 'D', associated assembly factors (WBSCR22--TRMT112 in state 'A'; RIOK2 in states 'C' and 'D') would sterically hinder the binding of METTL5--TRMT112. State 'B' shows no extra density in the area of interest. The assembly factors LTV1 (in blue), PNO1 (in green) and ENP1 (in orange), as well as helix 44 (h44, in pink) are shown for reference. PNO1 is detected in all five states while ENP1 is dissociated from pre-40S at the transition between states 'C' and 'D'. The region delimited by the dotted box corresponds to the region shown in panel B. (**B**) Zoom-in on an unassigned density present in pre-40S state 'E' (PDB 6G53; EMDB 4351) in the m^6^A-modified area, and tentative docking of the METTL5--TRMT112 structure. This tentative docking results in SAM being properly positioned with respect to the substrate adenosine. Color scheme as in panel (A). (**C**) Flag-tagged METTL5 co-purifies with PNO1 but not with ENP1. Expression of Flag-METTL5 was induced in HEK293 cells by addition of tetracycline and complexes containing Flag-METTL5 were captured on anti-Flag beads (see 'Materials and Methods' section). Co-precipitated proteins were detected by western blotting using the antibodies indicated. As control, a cell line expressing only the Flag-tag was used.](gkz619fig5){#F5}

Our identification of ZCCHC4 as the 28S rRNA m^6^A~4220~ methyltransferase is fully consistent with the results of a recent study ([@B19]), which additionally described a role of ZCCHC4 in HepG2 cell proliferation. We observed no comparable effect on the proliferation of HCT116 cells where the ZCCHC4 enzyme was inactivated by CRISPR--Cas9-mediated deletion of the active site signature (Figure [2A](#F2){ref-type="fig"}). It is unclear whether this discrepancy results from the different cell lines used in these studies or from the CRISPR--Cas9 protocol applied (in our case: transient exposure of cells to CRISPR--Cas9 complexes to minimize off-target effects).

When, during ribosome biogenesis, does METTL5--TRMT112 deposit the m^6^A mark on 18S rRNA? {#SEC4-1}
------------------------------------------------------------------------------------------

A pathway of late maturation of human pre-40S ribosomal subunits has recently been described, in which five discrete species (states 'A to E') appear in sequential order ([@B67], and summarized in Figure [5A](#F5){ref-type="fig"}). Prior to the present work, METTL5 was not known to be involved in human ribosome biogenesis, and to our knowledge, it had never been found associated with pre-40S human ribosomes. We therefore scrutinized the density maps of the cryo-EM structures of the five late pre-40S states to see if we might find, in the vicinity of position A~1832~, unattributed electron densities ascribable to METTL5--TRMT112.

Of the five pre-40S states only one, state 'E', retained our attention because it harbors, at the top of helix h44 in direct proximity to the m^6^A-modified residue A~1832~, an unassigned density that potentially corresponds to METTL5--TRMT112 (Figure [5A](#F5){ref-type="fig"} and [B](#F5){ref-type="fig"}). The other states are either incompatible with METTL5--TRMT112 binding because of the presence of assembly factors that would sterically interfere with it (WBSCR22--TRMT112 in the case of state 'A'; RIOK2, in the case of states 'C' and 'D', see Figure [5A](#F5){ref-type="fig"}), or simply because there is no density in the region of interest (state 'B').

In pre-40S state 'E', the local resolution of the unassigned density of interest on the cryoEM map is ∼8 Å. This precludes precise modeling of secondary structure elements. Nonetheless, we could tentatively dock the structure of the METTL5--TRMT112 complex in this density (Figure [5B](#F5){ref-type="fig"}), and this resulted in positioning its active site in close proximity to A~1832~ (orange dot in Figure [5B](#F5){ref-type="fig"}). Compatible with our hypothesis that METTL5--TRMT112 binds to pre-40S state 'E', Flag-tagged METTL5 co-purified PNO1, which is present in all five described pre-40S states, but not ENP1, which is dissociated from pre-40S ribosomes between states 'C' and 'D' (Figure [5C](#F5){ref-type="fig"}). Our results imply that m^6^A~1832~ formation is one of the last steps in 40S maturation and that it occurs after installation of m^7^G~1636~ by WBSCR22--TRMT112 (Figure [5A](#F5){ref-type="fig"}, state 'A'). In line with this hypothesis, we wondered whether one of these modifications (18S rRNA m^6^A~1832~ or m^7^G~1636~) might depend on prior deposition of the other ([Supplementary Figure S9](#sup1){ref-type="supplementary-material"}). As we found no major reduction of 18S rRNA m^6^A methylation in *wbscr22* -/- cells ([Supplementary Figure S9A](#sup1){ref-type="supplementary-material"}), lacking the m^7^G modification ([@B71]), and no reduction of 18S rRNA m^7^G methylation in *mettl5* -/- cells ([Supplementary Figure S9B](#sup1){ref-type="supplementary-material"}), lacking the m^6^A modification, we conclude these two modifications are formed independently.

How many TRMT112 molecules on each pre-40S subunit? {#SEC4-2}
---------------------------------------------------

TRMT112 is a very special protein because, in archaeal and eukaryal cells, it interacts with and activates multiple methyltransferases (at least 10 in archaea; 4 in budding yeast, and 5 in human cells) that modify factors (RNAs or proteins) involved in mRNA translation (see 'Introduction' and discussions in [@B47],[@B48]). In pre-40S ribosomes, remarkably, two complexes containing TRMT112, in association with either WBSCR22 or METTL5, act on neighboring areas (Figures [1A](#F1){ref-type="fig"} and [5A](#F5){ref-type="fig"},B). Although quite tempting, we do not favor the idea that TRMT112, once bound to pre-40S, acts as a recruitment platform for the successive association of WBSCR22 and METTL5, because in the structure of the pre-40S state 'A', TRMT112 is exposed toward the solvent, without any residues in direct contact with the pre-ribosome. Since both WBSCR22 and METTL5 depend upon their association with TRMT112 to gain metabolic stability (Figure [2E](#F2){ref-type="fig"} and [@B53]), we believe, rather, that both methyltransferases form heterodimers with TRMT112 independently and that these heterodimers coexist in cells. We therefore propose that the two methyltransferase heterodimers are recruited and act one after the other. Specifically, we suggest that WBSCR22--TRMT112 is recruited first, and that once it has performed its function and dissociated from pre-40S, METTL5--TRMT112 is recruited onto pre-40S.

On the importance of using multiple model organisms {#SEC4-3}
---------------------------------------------------

Until recently, the identification of the human partners of TRMT112 was based solely on characterization of human orthologs of known yeast Trm112 partners ([@B34], [@B51],[@B53],[@B72],[@B73]). Following this rationale, METTL5 would have escaped identification (yeast ribosomes are not m^6^A-modified at the position equivalent to human A~1832~, and yeast genomes do not encode METTL5 homologs). Here the approach was different: the present work on human cells stems from our recent characterization of the archaeal Trm112 interactome ([@B48]), which led us to identify *Hvo*Mettl5 (archaeal METTL5). This emphasizes the importance of conducting research on a range as diverse as possible of experimental models, including archaeal ones, which are sometimes neglected.
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